EYP-1901 Phase 2: Diabetic Macular Edema Study Results
Here’s a breakdown of the provided text, extracting key facts:
Main Topic: Results of the phase 2 VERONA study for EYP-1901 (vorolanib intravitreal insert) as a treatment for diabetic macular edema (DME).
key Findings:
EYP-1901: A bioerodible, sustained-release intravitreal insert delivering vorolanib.
Phase 2 VERONA Study: Met its primary endpoint – over 70% of patients receiving high-dose EYP-1901 reached 24 weeks without needing a supplemental injection.
repeat Treatment: approximately one-third of patients still required repeat treatment.
Monitoring: Patients will be monitored monthly too ensure they receive supplemental injections if needed.
Expert:
Yasha S. Modi, MD: NYU Langone Health. He discussed the results at the American Society of Retina Specialists annual meeting.
Disclosure: Dr. Modi reports consulting for EyePoint Pharmaceuticals.
Source:
Presentation by Yasha S.Modi at the American Society of Retina Specialists annual meeting (July 30-Aug. 2, 2025, Long Beach, California).
Publication:
Healio (specifically, Ocular Surgery News)
Related Links:
https://www.healio.com/news/ophthalmology/20250807/eyepoint-completes-enrollment-in-second-phase-3-trial-of-sustainedrelease-amd-therapy
https://www.healio.com/news/ophthalmology/20250206/duravyu-for-dme-meets-primary-secondary-endpoints-in-phase-2-trial